A phase I, open-label, multicenteir study to evaluate the safety and activity of rituximab in adults with relapsing-remitting multiple sclerosis (RRMS)

被引：0
作者：
Bar-Or, Amit
Calabresi, Peter
Arnold, Douglas
Markowitz, Clyde
Shafer, Stuart
Kasper, Lloyd
Waubant, Emmanuelle
Gazda, Suzanne
Fox, Robert
Sarkar, Neena
Panzara, Michael
Smith, Craig
机构：
来源：
NEUROLOGY | 2007年 / 68卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A84 / A84
页数：1
相关论文
共 50 条
  • [1] A phase 1, open-label, multicenter study to evaluate the safety and activity of rituximab in adults with relapsing-remitting multiple sclerosis (RRMS): 72 week results
    Bar-Or, Amit
    Calabresi, Peter
    Arnold, Douglas
    Markowitz, Clyde
    Shafer, Stuart
    Kasper, Lloyd
    Waubant, Emmanuelle
    Gazda, Suzanne
    Fox, Robert
    Sarkar, Neena
    Panzara, Michael
    Smith, Craig
    NEUROLOGY, 2008, 70 (11) : A119 - A120
  • [2] Safety, pharmacodynamics, and activity of rituximab in patients with relapsing-remitting multiple sclerosis: a phase I, multicentre, open-label clinical trial
    Bar-Or, A.
    Calabresi, P.
    Arnold, D. L.
    Markowitz, C.
    Shafer, S.
    Kasper, L.
    Waubant, E.
    Gazda, S.
    Fox, R.
    Panzara, M.
    Sarkar, N.
    Agarwal, S.
    Smith, C.
    MULTIPLE SCLEROSIS, 2007, 13 : S165 - S166
  • [3] Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
    Bar-Or, Amit
    Calabresi, Peter A. J.
    Arnlod, Douglas
    Markowitz, Clyde
    Shafer, Stuart
    Kasper, Lloyd H.
    Waubant, Ernmanuelle
    Gazda, Suzanne
    Fox, Robert J.
    Panzara, Michael
    Sarkar, Neena
    Agarwal, Sunil
    Smith, Craig H.
    ANNALS OF NEUROLOGY, 2008, 63 (03) : 395 - 400
  • [4] An open-label, prospective study of oral fumaric acid therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS)
    Schimrigk, SK
    Brune, N
    Hellwig, K
    Rieks, M
    Hoffmann, V
    Pohlau, D
    Przuntek, H
    NEUROLOGY, 2005, 64 (06) : A392 - A393
  • [5] Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
    Doosti, Rozita
    Moghadasi, Abdorreza Naser
    Azimi, Amir Reza
    Saleh, Shahrokh Karbalai
    Etemadifar, Masoud
    Shaygannejad, Vahid
    Ashtari, Fereshteh
    Harirchian, Mohammad Hossein
    Siroos, Seyed Bahaadin
    Ayramloo, Hormoz
    Majdinasab, Nastaran
    Hojjati, Seyyed Mohammad Masood
    Asghari, Nabiollah
    Baghbanian, Seyed Mohammad
    Cheraghmakani, Hamed
    Abedini, Mahmoud
    Sedighi, Behnaz
    Abadi, Negar Mohseni Abbas
    Ghasemitabar, Maedeh
    Talebianpour, Sara
    Daylari, Tohid Babayi
    Dana, Vahid
    Noie, Neda Ghaleh
    Sahraian, Mohammad Ali
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2021, 12 (03) : 263 - 274
  • [6] Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial
    Saida T.
    Kira J.-I.
    Kishida S.
    Yamamura T.
    Ohtsuka N.
    Ling Y.
    Torii S.
    Lucas N.
    Kuesters G.
    Steiner D.
    Tibung J.T.
    Neurology and Therapy, 2017, 6 (1) : 39 - 55
  • [7] A prospective, open-label, phase II study of oral fumarate therapy for the treatment of relapsing-remitting multiple sclerosis
    Schimrigk, S
    Brune, N
    Hellwig, K
    Rieks, M
    Hoffmann, V
    Pöhlau, D
    Przuntek, H
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S258 - S259
  • [8] Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
    Jai Perumal
    Roumen Balabanov
    Ray Su
    Roger Chang
    Laura Balcer
    Steven Galetta
    Denise I. Campagnolo
    Robin Avila
    Lily Lee
    Danette Rutledge
    Robert J. Fox
    Advances in Therapy, 2021, 38 : 3724 - 3742
  • [9] Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study
    Ordonez-Boschetti, Laura
    Rey, Roberto
    Cruz, Ana
    Sinha, Arijit
    Reynolds, Tracy
    Frider, Nadina
    Alvarenga, Regina
    ADVANCES IN THERAPY, 2015, 32 (07) : 626 - 635
  • [10] Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study
    Laura Ordoñez-Boschetti
    Roberto Rey
    Ana Cruz
    Arijit Sinha
    Tracy Reynolds
    Nadina Frider
    Regina Alvarenga
    Advances in Therapy, 2015, 32 : 626 - 635
12345